The University of Chicago Header Logo

Everett E. Vokes

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cameron RB, Hines JB, Torri V, Porcu L, Donington J, Bestvina CM, Vokes E, Dolezal JM, Esposito A, Garassino MC. What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446. PMID: 37720499; PMCID: PMC10504845.
      Citations:    
    2. Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023 Aug 18. PMID: 37597750.
      Citations:    Fields:    
    3. Bestvina CM, Garassino MC, Neal JW, Wakelee HA, Diehn M, Vokes EE. Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096. PMID: 37352477.
      Citations:    Fields:    Translation:Humans
    4. Wang X, McCaw ZR, Tian L, Stinchcombe TE, Vokes E, Ludmir EB, Wei LJ. Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies. JAMA Netw Open. 2023 06 01; 6(6):e2319055. PMID: 37342044; PMCID: PMC10285578.
      Citations:    Fields:    Translation:Humans
    5. Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE, Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722. PMID: 37182801.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    6. Forde PM, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N, Spicer J, Liberman M. Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. Future Oncol. 2023 Mar; 19(8):549-557. PMID: 36815433.
      Citations:    Fields:    Translation:Humans
    7. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes E. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023 02 09; 388(6):489-498. PMID: 36780674; PMCID: PMC10036605.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    8. Tran MC, Strohbehn GW, Karrison TG, Rouhani SJ, Segal JP, Shergill A, Hoffman PC, Patel JD, Garassino MC, Vokes EE, Bestvina CM. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121. PMID: 36806414.
      Citations:    Fields:    Translation:Humans
    9. Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, Heymach J, Bonner J, Kuzma C, Waqar S, Petty W, Stinchcombe TE, Bradley JD, Vokes E. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023 05 01; 41(13):2394-2402. PMID: 36623230; PMCID: PMC10150922.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    10. Leung TH, Ho JC, El Helali A, Vokes EE, Wang X, Pang H. New reporting items and recommendations for randomized trials impacted by COVID-19 and force majeure events: a targeted approach. Ann Transl Med. 2023 Jan 15; 11(1):2. PMID: 36760246; PMCID: PMC9906209.
      Citations:    
    11. Katipally RR, Spurr LF, Gutiontov SI, Turchan WT, Connell P, Juloori A, Malik R, Binkley MS, Jiang AL, Rouhani SJ, Chervin CS, Wanjari P, Segal JP, Ng V, Loo BW, Gomez DR, Bestvina CM, Vokes EE, Ferguson MK, Donington JS, Diehn M, Pitroda SP. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273. PMID: 36603171; PMCID: PMC10530422.
      Citations: 1     Fields:    Translation:Humans
    12. Nathan CO, Hayes DN, Karrison T, Harismendy O, Moore-Medlin T, Vokes EE, Gutkind JS, Neupane P, Mills G, Sargi Z, Seiwert T, Grilley-Olson J, Day T, Gillison M, Wade JL, Feldman L, Jha G, Kozloff M, O'Leary M, Worden FP, Cohen EEW, Flores JM. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048. PMID: 36194164; PMCID: PMC9722644.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    13. Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, Gutiontov SI, Turchan WT, Lynch CM, Pointer KB, Chang P, Murgu S, Husain AN, Cody B, Vokes EE, Bestvina CM, Patel JD, Diehn M, Gajewski TF, Weichselbaum RR, Chmura SJ, Pitroda SP. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 Nov 28. PMID: 36443406.
      Citations: 7     Fields:    
    14. Dolezal JM, Srisuwananukorn A, Karpeyev D, Ramesh S, Kochanny S, Cody B, Mansfield AS, Rakshit S, Bansal R, Bois MC, Bungum AO, Schulte JJ, Vokes EE, Garassino MC, Husain AN, Pearson AT. Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology. Nat Commun. 2022 Nov 02; 13(1):6572. PMID: 36323656; PMCID: PMC9630455.
      Citations: 4     Fields:    Translation:Humans
    15. Camidge DR, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K, Barlesi F. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115. PMID: 36288547; PMCID: PMC9928626.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    16. Rosenberg AJ, Agrawal N, Pearson AT, Gooi Z, Blair E, Portugal L, Cursio JF, Juloori A, Chin J, Rouse K, Villaflor VM, Seiwert TY, Izumchenko E, Lingen MW, Haraf DJ, Vokes EE. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506. PMID: 35945244; PMCID: PMC9553920.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    17. Hara JH, Gutiontov SI, Uddin S, Rosenberg AJ, Pearson AT, Gooi Z, Blair EA, Agrawal N, Vokes EE, Ginat DT, Haraf DJ, Juloori A. Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits. Cureus. 2022 Jul; 14(7):e27521. PMID: 36060366; PMCID: PMC9424785.
      Citations:    
    18. Vokes EE. 2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation. J Clin Oncol. 2022 09 01; 40(25):2859-2862. PMID: 35797507.
      Citations:    Fields:    Translation:Humans
    19. CheckMate 816 Investigators, Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 05 26; 386(21):1973-1985. PMID: 35403841.
      Citations: 269     Fields:    Translation:HumansCTClinical Trials
    20. Nair V, Auger S, Kochanny S, Howard FM, Ginat D, Pasternak-Wise O, Juloori A, Koshy M, Izumchenko E, Agrawal N, Rosenberg A, Vokes EE, Skandari MR, Pearson AT. Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Netw Open. 2022 04 01; 5(4):e227240. PMID: 35416988; PMCID: PMC9008506.
      Citations:    Fields:    Translation:HumansCells
    21. Gillison ML, Blumenschein G, Fayette J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL, Guigay J, Rordorf T. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist. 2022 03 04; 27(2):e194-e198. PMID: 35641218; PMCID: PMC8895496.
      Citations: 9     Fields:    Translation:Humans
    22. Rosenberg AJ, Izumchenko E, Pearson A, Gooi Z, Blair E, Karrison T, Juloori A, Ginat D, Cipriani N, Lingen M, Sloane H, Edelstein DL, Keyser K, Fredebohm J, Holtrup F, Jones FS, Haraf D, Agrawal N, Vokes EE. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17. PMID: 34980038; PMCID: PMC8722316.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    23. Camidge DR, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E, Hong DS, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K, Barlesi F. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clin Res Rep. 2022 Jan; 3(1):100262. PMID: 35005654; PMCID: PMC8717236.
      Citations: 1     
    24. Rosenberg AJ, Agrawal N, Pearson A, Gooi Z, Blair E, Cursio J, Juloori A, Ginat D, Howard A, Chin J, Kochanny S, Foster C, Cipriani N, Lingen M, Izumchenko E, Seiwert TY, Haraf D, Vokes EE. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566. PMID: 34662771; PMCID: PMC9295443.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    25. Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059. PMID: 34625620; PMCID: PMC8501138.
      Citations: 31     Fields:    Translation:Humans
    26. Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, Vokes EE, Weichselbaum RR, Pitroda SP, Patel JD, Chmura SJ. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140. PMID: 34500113.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    27. Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, Bernabe R, Syrigos K, Byers LA, Clingan P, Bar J, Vokes EE, Govindan R, Dunbar M, Ansell P, He L, Huang X, Sehgal V, Glasgow J, Bach BA, Mazieres J. Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol. 2021 11 10; 39(32):3633-3644. PMID: 34436928; PMCID: PMC8577684.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    28. Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792. PMID: 34426443.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    29. Kozono DE, Stinchcombe TE, Salama JK, Bogart J, Petty WJ, Guarino MJ, Bazhenova L, Larner JM, Weiss J, DiPetrillo TA, Feigenberg SJ, Chen X, Sun Z, Nuthalapati S, Rosenwinkel L, Johnson EF, Bach BA, Luo Y, Vokes EE. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65. PMID: 34311345.
      Citations: 5     Fields:    Translation:Humans
    30. Hensing TA, Wang X, Stinchcombe TE, Gao J, Knopp MV, Watson M, Dudek AZ, Graziano SL, Patel JD, Faller BA, Dragnev KH, Kozono D, Vokes EE. Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. JTO Clin Res Rep. 2021 Aug; 2(8):100208. PMID: 34590049; PMCID: PMC8474361.
      Citations:    
    31. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518. PMID: 34168049.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    32. Rao E, Hou Y, Huang X, Wang L, Wang J, Zheng W, Yang H, Yu X, Yang K, Bugno J, Ding X, Vokes E, Fu YX, Weichselbaum RR, Liang HL. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021 06 15; 6(60). PMID: 34723044; PMCID: PMC8550472.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    33. Liu X, Zhang Y, Li WF, Vokes E, Sun Y, Le QT, Ma J. Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. JAMA Netw Open. 2021 05 03; 4(5):e2110438. PMID: 34028549; PMCID: PMC8144925.
      Citations: 6     Fields:    Translation:Humans
    34. Juloori A, Vokes EE. Beyond PACIFIC: Uncharted Waters. J Thorac Oncol. 2021 05; 16(5):715-718. PMID: 33896569.
      Citations:    Fields:    Translation:Humans
    35. Pearson AT, Vokes EE. Is This the Dawn of Precision Oncology in Head and Neck Cancer? J Clin Oncol. 2021 06 10; 39(17):1839-1841. PMID: 33877869.
      Citations:    Fields:    Translation:Humans
    36. Bogart JA, Wang X, Masters GA, Gao J, Komaki R, Gaspar LE, Heymach JV, Dobelbower MC, Kuzma C, Stinchcombe TE, Vokes EE. Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. Lung Cancer. 2021 06; 156:68-71. PMID: 33894496; PMCID: PMC8418826.
      Citations: 5     Fields:    Translation:Humans
    37. Le QT, Grau C, Hackshaw A, Parmar MKB, Lee JW, Ghi MG, Sanguineti G, O'Sullivan B, Posner MR, Vokes EE, Cruz Hernandez JJ, Szutkowski Z, Lartigau E, Suwinski R, Poulsen M, Kumar S, Ghosh Laskar S, Jeremic B, Simes J, Zhong LP, Overgaard J, Fortpied C, Torres-Saavedra P, MACH-NC and MARCH Collaborative Groups, Petit C, Lacas B, Pignon JP, Grégoire V, Zackrisson B, Temam S, Cheugoua-Zanetsie M, Budach V, Mazeron JJ, Bourhis J, Aupérin A, Blanchard P. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021 05; 22(5):727-736. PMID: 33862002.
      Citations: 16     Fields:    Translation:Humans
    38. Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, Huang X, Wang L, Li L, Bugno J, Fu Y, Chmura SJ, Wu W, Luo SZ, Zheng W, Arina A, Jutzy J, McCall AR, Vokes EE, Pitroda SP, Fu YX, Weichselbaum RR. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582). PMID: 33627484; PMCID: PMC8710940.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    39. Jelinek MJ, Foster NR, Zoroufy AJ, Schwartz GK, Munster PN, Seiwert TY, de Souza JA, Vokes EE. A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. Oral Oncol. 2021 03; 114:105171. PMID: 33513474; PMCID: PMC7933088.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    40. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Chiari R, Butts C, Garassino MC, Ready N, Felip E, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J, Arrieta O, Frontera OA, Wójcik-Tomaszewska J, Coudert B, García MA, Czyzewicz G. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733. PMID: 33449799; PMCID: PMC8078445.
      Citations: 169     Fields:    Translation:Humans
    41. Reizine N, Vokes EE, Liu P, Truong TM, Nanda R, Fleming GF, Catenacci DVT, Pearson AT, Parsad S, Danahey K, van Wijk XMR, Yeo KJ, Ratain MJ, O'Donnell PH. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Ther Adv Med Oncol. 2020; 12:1758835920974118. PMID: 33414846; PMCID: PMC7750903.
      Citations: 3     
    42. Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 12; 21(12):1589-1601. PMID: 33125909; PMCID: PMC8109255.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    43. Onderdonk BE, Vokes EE, Gwede M, Blair E, Agrawal N, Haraf DJ. Adjuvant treatment for high-risk salivary gland malignancies and prognostic stratification based on a 20-year single institution experience. Health Sci Rep. 2020 Dec; 3(4):e195. PMID: 33043152; PMCID: PMC7539565.
      Citations:    
    44. Rosenberg AJ, Vokes EE. Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. Oncologist. 2021 01; 26(1):40-48. PMID: 32864799; PMCID: PMC7794179.
      Citations: 32     Fields:    Translation:HumansCells
    45. Dudek AZ, Wang X, Gu L, Duong S, Stinchcombe TE, Kratzke R, Borghaei H, Vokes EE, Kindler HL. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clin Lung Cancer. 2020 11; 21(6):553-561.e1. PMID: 32727707; PMCID: PMC7606734.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    46. Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, Wade JL, Sleckman BG, Anderson D, Brisson RJ, Karrison T, Stadler WM, Vokes EE. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243. PMID: 32365226.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    47. Grote HJ, Feng Z, Schlichting M, Helwig C, Ruisi M, Jin H, Scheuenpflug J, Gann CN, Su Z, Vokes EE, Kerr KM, Reck M. Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay. J Thorac Oncol. 2020 08; 15(8):1306-1316. PMID: 32353599.
      Citations: 10     Fields:    Translation:Humans
    48. Foster CC, Seiwert TY, MacCracken E, Blair EA, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Gooi Z, Spiotto MT, Vokes EE, Haraf DJ. Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes. Int J Radiat Oncol Biol Phys. 2020 07 15; 107(4):662-671. PMID: 32311416.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    49. Kochanny SE, Worden FP, Adkins DR, Lim DW, Bauman JE, Wagner SA, Brisson RJ, Karrison TG, Stadler WM, Vokes EE, Seiwert TY. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152. PMID: 32073648; PMCID: PMC8011819.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    50. Gooi Z, Vokes EE. Prolonging Life, but at What Price? JAMA Otolaryngol Head Neck Surg. 2019 12 01; 145(12):1103-1104. PMID: 31600372.
      Citations: 1     Fields:    Translation:Humans
    51. Stinchcombe TE, Wang X, Bertino EM, Weiss J, Bazhenova L, Gu L, Lau C, Paweletz C, Jaslowski A, Gerstner GJ, Baggstrom MQ, Graziano S, Bearden J, Vokes EE, Jänne PA. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Oct 01; 5(10):1448-1455. PMID: 31393548; PMCID: PMC6692685.
      Citations: 43     Fields:    
    52. Jelinek MJ, Vokes EE. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains? J Clin Oncol. 2019 11 01; 37(31):2807-2814. PMID: 31483688.
      Citations: 3     Fields:    Translation:HumansCells
    53. Brisson RJ, Kochanny S, Arshad S, Dekker A, DeSouza JA, Saloura V, Vokes EE, Seiwert TY. A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Head Neck. 2019 11; 41(11):3842-3849. PMID: 31486207; PMCID: PMC8258680.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    54. Strohbehn GW, Vokes EE. Palbociclib: a new partner for cetuximab? Lancet Oncol. 2019 09; 20(9):1195-1196. PMID: 31351868.
      Citations: 1     Fields:    Translation:HumansCells
    55. Govindan R, Senan S, Dickgreber N, Provencio M, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, Winfree K, Vokes EE, San Antonio B. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Curr Med Res Opin. 2019 10; 35(10):1761-1767. PMID: 31125266.
      Citations: 1     Fields:    Translation:Humans
    56. Haddad R, Concha-Benavente F, Blumenschein G, Fayette J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL, Guigay J. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019 09 15; 125(18):3208-3218. PMID: 31246283; PMCID: PMC6771504.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    57. Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G, Harrington KJ, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML, Guigay J. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230. PMID: 31239321; PMCID: PMC7721346.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    58. Ganti AK, Wang X, Stinchcombe TE, Wang Y, Bradley J, Cohen HJ, Kelly K, Paulus R, Ramalingam SS, Vokes EE, Pang H. Clinical prognostic model for older patients with advanced non-small cell lung cancer. J Geriatr Oncol. 2019 07; 10(4):555-559. PMID: 30797707; PMCID: PMC7136030.
      Citations: 3     Fields:    Translation:Humans
    59. Ren L, Deng B, Matsuda T, Kiyotani K, Kato T, Harada M, Park JH, Saloura V, Seiwert T, Vokes E, Agrawal N, Nakamura Y, Leisegang M. Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. Oncoimmunology. 2019; 8(4):e1568813. PMID: 30906664; PMCID: PMC6422382.
      Citations: 24     Fields:    
    60. Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Jones DR, Keenan R, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ, Liberman M, Conti M. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018 12; 6(12):915-924. PMID: 30442588; PMCID: PMC6396275.
      Citations: 118     Fields:    Translation:HumansCTClinical Trials
    61. Stinchcombe TE, Fan W, Schild SE, Vokes EE, Bogart J, Le QT, Thomas CR, Edelman MJ, Horn L, Komaki R, Cohen HJ, Kishor Ganti A, Pang H, Wang X. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. 2019 02 01; 125(3):382-390. PMID: 30343497; PMCID: PMC6340765.
      Citations: 5     Fields:    Translation:Humans
    62. Schild SE, Fan W, Stinchcombe TE, Vokes EE, Ramalingam SS, Bradley JD, Kelly K, Pang HH, Wang X. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 02; 14(2):298-303. PMID: 30292852; PMCID: PMC6348032.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    63. Jelinek MJ, Howard AS, Haraf DJ, Vokes EE. Management of Early Head and Neck Cancer in Elderly Patients. J Oncol Pract. 2018 09; 14(9):541-546. PMID: 30285530.
      Citations: 3     Fields:    Translation:Humans
    64. Mambetsariev I, Pharaon R, Nam A, Knopf K, Djulbegovic B, Villaflor VM, Vokes EE, Salgia R. Heuristic value-based framework for lung cancer decision-making. Oncotarget. 2018 Jul 06; 9(52):29877-29891. PMID: 30042820; PMCID: PMC6057456.
      Citations: 3     Fields:    
    65. Gillison ML, Blumenschein G, Fayette J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL, Guigay J, Rordorf T. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist. 2018 09; 23(9):1079-1082. PMID: 29866947; PMCID: PMC6221824.
      Citations: 34     Fields:    Translation:Humans
    66. Vokes EE, Govindan R, Iscoe N, Hossain AM, San Antonio B, Chouaki N, Koczywas M, Senan S. The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. J Thorac Oncol. 2018 08; 13(8):1183-1188. PMID: 29733908.
      Citations: 5     Fields:    Translation:Humans
    67. Schild SE, Pang HH, Fan W, Stinchcombe TE, Vokes EE, Ramalingam SS, Bradley JD, Kelly K, Wang X. Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. J Thorac Oncol. 2018 08; 13(8):1171-1182. PMID: 29689435.
      Citations: 9     Fields:    Translation:Humans
    68. Ferris RL, Blumenschein G, Fayette J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML, Guigay J, Rordorf T. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 06; 81:45-51. PMID: 29884413; PMCID: PMC6563923.
      Citations: 281     Fields:    Translation:Humans
    69. Poroyko V, Mirzapoiazova T, Nam A, Mambetsariev I, Mambetsariev B, Wu X, Husain A, Vokes EE, Wheeler DL, Salgia R. Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. Oncotarget. 2018 Apr 13; 9(28):19793-19806. PMID: 29731983; PMCID: PMC5929426.
      Citations: 21     Fields:    
    70. Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Gettinger S, Holgado E, Spigel D, Waterhouse D, Garassino M, Chow LQM, Blumenschein G, Gainor J, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Arén Frontera O, Domine M, Barlesi F, Coudert B, Arrieta O, Crinò L. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018 04 01; 29(4):959-965. PMID: 29408986.
      Citations: 216     Fields:    Translation:Humans
    71. Shukla ND, Salahudeen AA, Taylor GA, Ramalingam SS, Vokes EE, Goss GD, Decker RH, Kelly K, Scagliotti GV, Mok TS, Wakelee HA. Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. Clin Lung Cancer. 2018 09; 19(5):377-386. PMID: 29653819.
      Citations:    Fields:    Translation:Humans
    72. Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EEW, Stenson KM, Blair EA, Portugal L, Gooi Z, Agrawal N, Vokes EE, Haraf DJ. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22. PMID: 29706184.
      Citations: 13     Fields:    Translation:Humans
    73. Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, Fischer JS, Chu KL, Ames WW, Mittapalli RK, Lee HJ, Zeng J, Roberts-Rapp LA, Loberg LI, Ansell PJ, Reilly EB, Ocampo CJ, Holen KD, Tolcher AW. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer. 2018 05 15; 124(10):2174-2183. PMID: 29533458; PMCID: PMC5969257.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    74. Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185. PMID: 29487024; PMCID: PMC6173195.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    75. Yesensky JA, Hasina R, Wroblewski KE, Bellairs J, Gooi Z, Saloura V, Cipriani NA, Vokes EE, Portugal LG, Seiwert TY, Blair ED, Agrawal N. Role of dental hardware in oral cavity squamous cell carcinoma in the low-risk nonsmoker nondrinker population. Head Neck. 2018 04; 40(4):784-792. PMID: 29356169.
      Citations: 3     Fields:    Translation:Humans
    76. Ren L, Matsuda T, Deng B, Kiyotani K, Kato T, Park JH, Seiwert TY, Vokes EE, Agrawal N, Nakamura Y. Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer. Oncotarget. 2018 Jan 09; 9(3):3805-3814. PMID: 29423084; PMCID: PMC5790501.
      Citations: 4     Fields:    
    77. Stoy SP, Segal JP, Mueller J, Furtado LV, Vokes EE, Patel JD, Murgu S. Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non-small-cell Lung Cancer. Clin Lung Cancer. 2018 05; 19(3):230-238.e2. PMID: 29277564.
      Citations: 29     Fields:    Translation:Humans
    78. Bestvina CM, Vokes EE. ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards. Lancet Oncol. 2017 12; 18(12):1555-1556. PMID: 29074100.
      Citations:    Fields:    Translation:Humans
    79. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10; 35(35):3924-3933. PMID: 29023213; PMCID: PMC6075826.
      Citations: 394     Fields:    Translation:HumansCTClinical Trials
    80. Tan YC, Mirzapoiazova T, Won BM, Zhu L, Srivastava MK, Vokes EE, Husain AN, Batra SK, Sharma S, Salgia R. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192. PMID: 28835699; PMCID: PMC5569108.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    81. Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Fayette J, Grünwald V, Guigay J. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1104-1115. PMID: 28651929; PMCID: PMC6461049.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    82. Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892. PMID: 28493811; PMCID: PMC5578390.
      Citations: 26     Fields:    Translation:Humans
    83. Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE, Alliance for Clinical Trials in Oncology. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192. PMID: 28489511; PMCID: PMC5493050.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    84. Saloura V, Fatima A, Zewde M, Kiyotani K, Brisson R, Park JH, Ikeda Y, Vougiouklakis T, Bao R, Khattri A, Seiwert T, Cipriani N, Lingen M, Vokes E, Nakamura Y. Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2017 Aug 15; 23(16):4897-4907. PMID: 28442504.
      Citations: 12     Fields:    Translation:HumansCells
    85. Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734. PMID: 27244893; PMCID: PMC5386642.
      Citations: 2     Fields:    Translation:Humans
    86. Wang X, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Ganti AK, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist. 2017 02; 22(2):189-198. PMID: 28188257; PMCID: PMC5330706.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    87. Baggstrom MQ, Socinski MA, Wang XF, Gu L, Stinchcombe TE, Edelman MJ, Baker S, Feliciano J, Novotny P, Hahn O, Crawford JA, Vokes EE. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol. 2017 05; 12(5):843-849. PMID: 28161554; PMCID: PMC5500219.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    88. Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C, Paz-Ares L, Pérol M. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open. 2016; 1(6):e000118. PMID: 29435365; PMCID: PMC5729303.
      Citations: 2     
    89. Gooi Z, Richmon J, Agrawal N, Blair E, Portugal L, Vokes E, Seiwert T, de Souza J, Saloura V, Haraf D, Goldenberg D, Chan J. AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines. Head Neck. 2017 02; 39(2):201-205. PMID: 27898198.
      Citations: 5     Fields:    Translation:Humans
    90. Olugbile S, Kiyotani K, Park JH, Hoffman P, Szeto L, Patel J, Vokes E, Nakamura Y. PS01.05: Early and Persistent Oligoclonal T Cell Expansion Correlates with Durable Response to Anti-PD1 Therapy in NSCLC: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S272. PMID: 27969473.
      Citations:    
    91. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 11 10; 375(19):1856-1867. PMID: 27718784; PMCID: PMC5564292.
      Citations: 1858     Fields:    Translation:HumansCTClinical Trials
    92. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Felip E, Fennell D, Moniuszko M, Novello S, Papotti M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E, Crinò L, Garrido P, Huber RM, Marabelle A, Mornex F, Pérol M. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 02; 12(2):194-207. PMID: 27729297.
      Citations: 110     Fields:    Translation:Humans
    93. Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999. PMID: 27646951; PMCID: PMC5477832.
      Citations: 40     Fields:    Translation:Humans
    94. Dittrich C, Kosty M, Jezdic S, Pyle D, Bergh J, El-Saghir N, Pavlidis N, Purkalne G, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Homicsko K, Jones DV, Jost L, Khan S, Kiss A, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Palumbo A, Peccatori FA, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y, Berardi R, Lotz JP, Österlund P, Awada A, Herrstedt J, Keilholz U, Köhne CH, Litière S, Meran JG, Öberg K, Pfeilstöcker M, Schlumberger M, Stupp R. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016; 1(5):e000097. PMID: 27843641; PMCID: PMC5070299.
      Citations: 38     
    95. Goldman JW, Crino L, Vokes EE, Holgado E, Reckamp K, Pluzanski A, Spigel D, Kohlhaeufl M, Garassino M, Chow LQ, Gettinger S, Gerber DE, Havel L, Ramalingam SS, Dy GK, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Lopes G. P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy. J Thorac Oncol. 2016 Oct; 11(10S):S238-S239. PMID: 27676570.
      Citations:    
    96. Salahudeen AA, Patel MI, Baas P, Curran WJ, Bradley JD, Gandara DR, Goss GD, Mok TS, Ramalingam SS, Vokes EE, Malik SM, Wakelee HA. Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clin Lung Cancer. 2017 01; 18(1):5-12. PMID: 27473736; PMCID: PMC5361177.
      Citations: 1     Fields:    Translation:Humans
    97. Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9. PMID: 27511844.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    98. Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86. PMID: 26934441; PMCID: PMC4951336.
      Citations: 10     Fields:    Translation:Humans
    99. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, Chouaki N, Vokes E, Rubio-Viqueira B, San Antonio B. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 20; 34(9):953-62. PMID: 26811519.
      Citations: 160     Fields:    Translation:HumansCTClinical Trials
    100. Salama JK, Gu L, Wang X, Pang HH, Bogart JA, Crawford J, Schild SE, Vokes EE, Ready NE. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). J Thorac Oncol. 2016 Mar; 11(3):361-9. PMID: 26723241; PMCID: PMC4775320.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    101. Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Gandara DR, Ramalingam SS, Vokes EE, Jänne PA. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44. PMID: 26672084; PMCID: PMC4683399.
      Citations: 51     Fields:    Translation:Humans
    102. Vokes EE, Agrawal N, Seiwert TY. HPV-Associated Head and Neck Cancer. J Natl Cancer Inst. 2015 Dec; 107(12):djv344. PMID: 26656751.
      Citations: 70     Fields:    Translation:HumansCells
    103. Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Arrieta O, Burgio MA, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Blumenschein GR, Antonia SJ, Harbison CT, Graf Finckenstein F, Brahmer JR, Borghaei H, Kohlhäufl M, Fayette J, Lena H, Crinò L, Dorange C. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22; 373(17):1627-39. PMID: 26412456; PMCID: PMC5705936.
      Citations: 4073     Fields:    Translation:HumansCTClinical Trials
    104. Wang X, Gu L, Zhang Y, Sargent DJ, Richards W, Ganti AK, Crawford J, Cohen HJ, Stinchcombe T, Vokes E, Pang H. Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer. 2015 Nov; 90(2):281-7. PMID: 26319317; PMCID: PMC4619143.
      Citations: 3     Fields:    Translation:Humans
    105. Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen CT, Murgu SD, Vokes EE, Vannier MW, Salgia R. Lung cancer-a fractal viewpoint. Nat Rev Clin Oncol. 2015 Nov; 12(11):664-75. PMID: 26169924; PMCID: PMC4989864.
      Citations: 63     Fields:    Translation:Humans
    106. Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ, Foster NR. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106. PMID: 26134227; PMCID: PMC4493926.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    107. Ferguson BD, Carol Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, John Iafrate A, Gill PS, Salgia R. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641. PMID: 26073592; PMCID: PMC4466581.
      Citations: 12     Fields:    Translation:HumansCells
    108. Reckamp KL, Baas P, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR, Brahmer J, Crinò L, Arén Frontera O. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35. PMID: 26028407; PMCID: PMC4681400.
      Citations: 3669     Fields:    Translation:HumansCTClinical Trials
    109. Sasaki MM, Skol AD, Bao R, Rhodes LV, Chambers R, Vokes EE, Cohen EE, Onel K. Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1222-8. PMID: 26014803; PMCID: PMC4526396.
      Citations: 13     Fields:    Translation:Humans
    110. Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen EE. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res. 2015 May; 3(5):567-74. PMID: 25769300; PMCID: PMC4681575.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    111. Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20; 33(15):1660-5. PMID: 25732163; PMCID: PMC4429175.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    112. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24. PMID: 25680375; PMCID: PMC4654466.
      Citations: 97     Fields:    Translation:HumansCTClinical Trials
    113. Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968. PMID: 25667282.
      Citations:    Fields:    Translation:Humans
    114. Saloura V, Vokes EE. EGFR-based bioradiotherapy in SCCHN. Lancet Oncol. 2015 Feb; 16(2):129-30. PMID: 25596658.
      Citations: 2     Fields:    Translation:Humans
    115. Samuels M, Wang X, Kong FM, Masters G, Katragadda S, Hodgson L, Bogart J, Bradley J, Vokes E, Lilenbaum R, Jänne PA. A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol. 2015 Jan; 10(1):143-7. PMID: 25384173; PMCID: PMC4320012.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    116. Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY, Brägelmann J. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81. PMID: 25492084.
      Citations: 163     Fields:    Translation:HumansCells
    117. Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EEW, Seiwert TY, Haraf DJ, Vokes EE. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205. PMID: 25361984.
      Citations: 3     Fields:    Translation:HumansCells
    118. Khattri A, Zuo Z, Keck MK, El Dinali M, Brown CD, Stricker T, Munagala A, Cohen EE, Lingen MW, White KP, Vokes EE, Seiwert TY, Brägelmann J. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8. PMID: 25255959.
      Citations: 9     Fields:    Translation:HumansCells
    119. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS, Brägelmann J. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41. PMID: 25056374; PMCID: PMC4305034.
      Citations: 299     Fields:    Translation:HumansCells
    120. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43. PMID: 25049329; PMCID: PMC4876357.
      Citations: 157     Fields:    Translation:HumansCTClinical Trials
    121. Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, Cohen EE, Stenson K, Weaver DT, Vokes EE. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112. PMID: 25019640; PMCID: PMC4096922.
      Citations: 6     Fields:    Translation:HumansCells
    122. Geeleher P, Zuo Z, Weichselbaum RR, Vokes EE, Seiwert TY, Heitmann J, Fetscher S. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncol. 2014 Sep; 50(9):825-31. PMID: 25017803.
      Citations: 4     Fields:    Translation:HumansCells
    123. Kanteti R, El-Hashani E, Dhanasingh I, Tretiakova M, Husain AN, Sharma S, Sharma J, Vokes EE, Salgia R. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185. PMID: 24628993; PMCID: PMC3995599.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    124. Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA, Alliance for Clinical Trials in Oncology, Heist RS. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9(2):214-21. PMID: 24419419; PMCID: PMC4284815.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    125. Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5. PMID: 24386952; PMCID: PMC3893521.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    126. Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84. PMID: 24327519; PMCID: PMC4286701.
      Citations: 13     Fields:    Translation:HumansCells
    127. Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95. PMID: 24305878; PMCID: PMC5841456.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    128. Salama JK, Pang H, Bogart JA, Blackstock AW, Urbanic JJ, Hogson L, Crawford J, Vokes EE. Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. Lung Cancer. 2013 Dec; 82(3):436-40. PMID: 24396884; PMCID: PMC4098705.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    129. Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R. O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. J Carcinog. 2013; 12:20. PMID: 24319345; PMCID: PMC3853796.
      Citations: 9     
    130. Zakeri K, MacEwan I, Vazirnia A, Cohen EE, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4. PMID: 24134948.
      Citations: 9     Fields:    Translation:Humans
    131. Salama JK, Hodgson L, Pang H, Urbanic JJ, Blackstock AW, Schild SE, Crawford J, Bogart JA, Vokes EE, Cancer and Leukemia Group B. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013 Aug; 8(8):1043-9. PMID: 23715301; PMCID: PMC3822578.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    132. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70. PMID: 23900000; PMCID: PMC3755935.
      Citations: 5     Fields:    Translation:HumansCells
    133. Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668. PMID: 23844053; PMCID: PMC3699624.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    134. Maggiore RJ, Curran EK, Witt ME, Haraf DJ, Vokes EE, Cohen EE. Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. J Geriatr Oncol. 2013 Oct; 4(4):327-33. PMID: 24472475; PMCID: PMC4413907.
      Citations: 9     Fields:    Translation:Humans
    135. Vokes EE, Seiwert TY. EGFR-directed treatments in SCCHN. Lancet Oncol. 2013 Jul; 14(8):672-3. PMID: 23746667.
      Citations: 6     Fields:    Translation:Humans
    136. Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA, Salgia R. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther. 2013 Jul; 14(7):679-91. PMID: 23792636; PMCID: PMC3742497.
      Citations: 22     Fields:    Translation:HumansCells
    137. Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY, Brägelmann J. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33. PMID: 23490885.
      Citations: 14     Fields:    Translation:HumansCells
    138. Salama JK, Vokes EE. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1029-38. PMID: 23401449.
      Citations: 37     Fields:    Translation:Humans
    139. Schiller JH, Gandara DR, Goss GD, Vokes EE. Non-small-cell lung cancer: then and now. J Clin Oncol. 2013 Mar 10; 31(8):981-3. PMID: 23401450.
      Citations: 15     Fields:    Translation:HumansPHPublic Health
    140. Vokes EE. Competing roads to larynx preservation. J Clin Oncol. 2013 Mar 01; 31(7):833-5. PMID: 23341522.
      Citations: 5     Fields:    Translation:Humans
    141. Kelley MJ, Bogart JA, Hodgson LD, Ansari RH, Atkins JN, Pang H, Green MR, Vokes EE. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. J Thorac Oncol. 2013 Jan; 8(1):102-8. PMID: 23196276; PMCID: PMC3524334.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    142. Vokes EE, Salgia R, Karrison TG. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9. PMID: 23251009.
      Citations: 12     Fields:    Translation:Humans
    143. Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76. PMID: 23104721; PMCID: PMC3662388.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    144. Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, Armato SG, Kindler HL, Salgia R. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. BMJ Open. 2012; 2(5). PMID: 23103606; PMCID: PMC3488720.
      Citations: 3     Fields:    
    145. Golden DW, Rudra S, Witt ME, Nwizu T, Cohen EE, Blair E, Stenson KM, Vokes EE, Haraf DJ. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82. PMID: 23102863.
      Citations: 7     Fields:    Translation:Humans
    146. Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94. PMID: 23100466.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    147. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80. PMID: 22831987; PMCID: PMC4319647.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    148. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE, Jänne PA. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. PMID: 22665541; PMCID: PMC3397785.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    149. Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EEW, Vokes EE, List M, Haraf DJ, Salama JK. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030. PMID: 22621836.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    150. Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R. Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer. 2012 Sep; 51(9):841-51. PMID: 22585712.
      Citations: 21     Fields:    Translation:HumansCells
    151. Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA, Jänne PA. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol. 2012 Jun 10; 30(17):2063-9. PMID: 22547605; PMCID: PMC3397694.
      Citations: 116     Fields:    Translation:HumansCTClinical Trials
    152. Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen EE. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92. PMID: 22513208.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    153. Edelman MJ, Hodgson L, Wang X, Kratzke RA, Vokes EE. Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. J Clin Oncol. 2012 Jun 01; 30(16):2019-20; author reply 2020. PMID: 22473168; PMCID: PMC3383177.
      Citations: 6     Fields:    Translation:Humans
    154. Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, Kratzke R. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012 Apr; 7(4):649-54. PMID: 22425913; PMCID: PMC5541770.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    155. Dudek AZ, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HL, Cancer and Leukemia Group B. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7(4):755-9. PMID: 22425926; PMCID: PMC3308128.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    156. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8. PMID: 22198425; PMCID: PMC3288403.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    157. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43. PMID: 22371453; PMCID: PMC4467891.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    158. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81. PMID: 22198429.
      Citations: 36     Fields:    Translation:Humans
    159. Mauceri HJ, Sutton HG, Darga TE, Kocherginsky M, Kochanski J, Weichselbaum RR, Vokes EE. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol Rep. 2012 May; 27(5):1625-9. PMID: 22294050.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    160. Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, Green M, Vokes EE, Kindler HL. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6. PMID: 22197613; PMCID: PMC4778731.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    161. Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8. PMID: 22100149.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    162. Stenson KM, Maccracken E, Kunnavakkam R, W Cohen EE, Portugal LD, Villaflor V, Seiwert T, Blair E, Haraf DJ, Salama JK, Vokes EE. Chemoradiation for patients with large-volume laryngeal cancers. Head Neck. 2012 Aug; 34(8):1162-7. PMID: 22052816.
      Citations: 5     Fields:    Translation:Humans
    163. Edelman MJ, Hodgson L, Wang X, Christenson R, Jewell S, Vokes E, Kratzke R. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. J Thorac Oncol. 2011 Nov; 6(11):1902-6. PMID: 21964530; PMCID: PMC5673085.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    164. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70. PMID: 22020702.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    165. Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011 Nov 20; 29(33):4436-41. PMID: 21969504; PMCID: PMC3221525.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    166. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. PMID: 21716143; PMCID: PMC3220078.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    167. Pederson AW, Salama JK, Witt ME, Stenson KM, Blair EA, Vokes EE, Haraf DJ. Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. Am J Clin Oncol. 2011 Aug; 34(4):356-61. PMID: 21633289.
      Citations: 13     Fields:    Translation:Humans
    168. Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31. PMID: 21791072; PMCID: PMC3189162.
      Citations: 14     Fields:    Translation:Humans
    169. Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, Garst J, Brotherton T, Vokes EE. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. 2011 Aug 10; 29(23):3120-5. PMID: 21747084; PMCID: PMC3157978.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    170. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R, Brägelmann J. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46. PMID: 21543897; PMCID: PMC3149873.
      Citations: 50     Fields:    Translation:HumansCells
    171. Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8. PMID: 21671479.
      Citations: 20     Fields:    Translation:Humans
    172. Barreto-Andrade JC, Efimova EV, Mauceri HJ, Beckett MA, Sutton HG, Darga TE, Vokes EE, Posner MC, Kron SJ, Weichselbaum RR. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther. 2011 Jul; 10(7):1185-93. PMID: 21571912; PMCID: PMC3140695.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    173. Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S, Sleckman BG, Taber D, Vokes EE, Stadler WM, Kindler HL. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5. PMID: 21552992; PMCID: PMC4317401.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    174. Masters GA, Wang X, Hodgson L, Shea T, Vokes E, Green M. A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Lung Cancer. 2011 Nov; 74(2):258-63. PMID: 21529989; PMCID: PMC5656235.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    175. Salama JK, Stinchcombe TE, Gu L, Wang X, Morano K, Bogart JA, Crawford JC, Socinski MA, Blackstock AW, Vokes EE, Cancer and Leukemia Group B. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e269-74. PMID: 21477940; PMCID: PMC3135692.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    176. Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83. PMID: 21421117.
      Citations: 19     Fields:    Translation:HumansCells
    177. Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EEW. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507. PMID: 21385883.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    178. Loganathan S, Kanteti R, Siddiqui SS, El-Hashani E, Tretiakova M, Vigneswaran H, Cervantes G, Natarajan V, Husain AN, Vokes EE, Kindler HL, Salgia R. Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism. J Carcinog. 2011 Mar 03; 10:4. PMID: 21383961; PMCID: PMC3049271.
      Citations: 3     
    179. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma. 2011 Feb 28; 1(8):1-11. PMID: 21603121; PMCID: PMC3164615.
      Citations: 7     
    180. Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, Kunnavakkam R, Cohen EE, Seiwert T, Vokes EE. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9. PMID: 21330337.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    181. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen EE, Dolan ME, Huang RS. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72. PMID: 21497773; PMCID: PMC3079878.
      Citations: 32     Fields:    Translation:HumansCells
    182. Nwizu T, Kanteti R, Kawada I, Rolle C, Vokes EE, Salgia R. Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. Drugs Future. 2011 Feb; 36(2):91-99. PMID: 26412935; PMCID: PMC4582997.
      Citations: 3     
    183. Brockstein BE, Vokes EE. Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol. 2011 Feb; 8(2):72-4. PMID: 21278773.
      Citations: 13     Fields:    Translation:Humans
    184. Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, Salgia R. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54. PMID: 22181983.
      Citations: 11     Fields:    Translation:HumansCells
    185. Mouw KW, Haraf DJ, Stenson KM, Cohen EE, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34. PMID: 21173372.
      Citations: 6     Fields:    Translation:Humans
    186. Pederson AW, Haraf DJ, Witt ME, Stenson KM, Vokes EE, Blair EA, Salama JK. Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. Head Neck. 2010 Nov; 32(11):1519-27. PMID: 20187015.
      Citations: 7     Fields:    Translation:Humans
    187. Brockstein B, Vokes EE. Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries. Nat Rev Clin Oncol. 2010 Nov; 7(11):616-8. PMID: 20981124.
      Citations:    Fields:    Translation:Humans
    188. Choe KS, Salama JK, Stenson KM, Blair EA, Witt ME, Cohen EE, Haraf DJ, Vokes EE. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21. PMID: 20934766.
      Citations: 3     Fields:    Translation:Humans
    189. Dubey S, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL, Jänne PA. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61. PMID: 20736856; PMCID: PMC3823555.
      Citations: 39     Fields:    Translation:HumansCellsCTClinical Trials
    190. Otterson GA, Hodgson L, Pang H, Vokes EE, Cancer and Leukemia Group B. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol. 2010 Oct; 5(10):1644-8. PMID: 20871263; PMCID: PMC3782083.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    191. Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, Rosner MR, Cohen EE. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24. PMID: 20876745; PMCID: PMC2953602.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    192. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6. PMID: 20837940; PMCID: PMC3020703.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    193. Ready N, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE, Cancer, Leukemia Group B, Chicago, IL, Jänne PA. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010 Sep; 5(9):1382-90. PMID: 20686428.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    194. Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6. PMID: 20803052; PMCID: PMC4319645.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    195. Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61. PMID: 20730572.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    196. Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara DR. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010 Aug; 5(8):1279-84. PMID: 20559150; PMCID: PMC2911495.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    197. Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, Kratzke R, Dudek AZ, Vokes EE, Green MR, Cancer and Leukemia Group B, North Central Cancer Treatment Group, Radiation Therapy Oncology Group. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol. 2010 Jun; 5(6):810-7. PMID: 20521348; PMCID: PMC3505667.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    198. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43. PMID: 20498391; PMCID: PMC2903330.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    199. Pederson AW, Haraf DJ, Blair EA, Stenson KM, Witt ME, Vokes EE, Salama JK. Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol. 2010 Jun; 95(3):308-11. PMID: 20385414.
      Citations: 12     Fields:    Translation:Humans
    200. Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem. 2010 Jun 11; 285(24):18575-85. PMID: 20360610; PMCID: PMC2881783.
      Citations: 65     Fields:    Translation:HumansCells
    201. Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, Kratzke RA, Vokes EE, Cancer and Leukemia Group B (CALGB). A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol. 2010 Mar; 5(3):380-4. PMID: 20087228; PMCID: PMC2853764.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    202. Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost JA, Wade JL, Agamah E, Vokes EE, Fleming GF. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010 Apr; 117(1):37-40. PMID: 20117828; PMCID: PMC2842466.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    203. Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia R. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972. PMID: 20126411; PMCID: PMC2813301.
      Citations: 60     Fields:    Translation:HumansCells
    204. Vokes EE. Induction chemotherapy for head and neck cancer: recent data. Oncologist. 2010; 15 Suppl 3:3-7. PMID: 21036882.
      Citations: 25     Fields:    Translation:Humans
    205. Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, Salama J, Vokes EE. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9. PMID: 19856305.
      Citations: 28     Fields:    Translation:Humans
    206. Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, McNeil BJ. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol. 2010 Jan 10; 28(2):215-21. PMID: 19933919; PMCID: PMC2815711.
      Citations: 9     Fields:    Translation:Humans
    207. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, Belani CP. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 01; 28(1):56-62. PMID: 19933908; PMCID: PMC2799233.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    208. Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20. PMID: 19933920.
      Citations: 49     Fields:    Translation:Humans
    209. Bogart JA, Hodgson L, Seagren SL, Blackstock AW, Wang X, Lenox R, Turrisi AT, Reilly J, Gajra A, Vokes EE, Green MR. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol. 2010 Jan 10; 28(2):202-6. PMID: 19933904; PMCID: PMC2815709.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    210. Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov; 14(11):1116-30. PMID: 19892771.
      Citations: 21     Fields:    Translation:Humans
    211. Langerman A, Plein C, Vokes EE, Salama JK, Haraf DJ, Blair EA, Stenson KM. Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Nov; 135(11):1133-6. PMID: 19917927.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    212. Wakelee H, Loo BW, Kernstine KH, Putnam JB, Edelman MJ, Vokes EE, Schiller JH, Baas P, Saijo N, Adjei A, Goss G, Choy H, Gandara DR. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin Lung Cancer. 2009 Nov; 10(6):395-404. PMID: 19900856.
      Citations: 1     Fields:    Translation:Humans
    213. Stinchcombe TE, Hodgson L, Herndon JE, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE, Cancer and Leukemia Group B. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9):1117-25. PMID: 19652624; PMCID: PMC2778485.
      Citations: 15     Fields:    Translation:Humans
    214. Sangha R, Lara PN, Adjei AA, Baas P, Choy H, Gaspar LE, Goss G, Saijo N, Schiller JH, Vokes EE, Gandara DR. Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer. 2009 Sep; 10(5):322-30. PMID: 19808190.
      Citations: 1     Fields:    Translation:Humans
    215. Langerman A, Comstock R, Konda S, Abramovitch A, Kasza K, Vokes EE, Stenson KM. Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Sep; 135(9):876-80. PMID: 19770419.
      Citations:    Fields:    Translation:Humans
    216. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, Ferguson MK, Natarajan V, Wang YC, Garcia JG, Vokes EE, Salgia R. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23. PMID: 19723643; PMCID: PMC2767337.
      Citations: 96     Fields:    Translation:Humans
    217. Lilenbaum R, Wang X, Gu L, Kirshner J, Lerro K, Vokes E. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol. 2009 Sep 20; 27(27):4487-91. PMID: 19704058; PMCID: PMC2754901.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    218. Nimeiri HS, Singh DA, Kasza K, Taber DA, Ansari RH, Vokes EE, Kindler HL. The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2010 Dec; 28(6):854-8. PMID: 19669700; PMCID: PMC4635688.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    219. Choong NW, Kozloff M, Taber D, Hu HS, Wade J, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83. PMID: 19649772.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    220. Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21. PMID: 19340870.
      Citations: 10     Fields:    Translation:Humans
    221. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol. 2009 Aug 10; 27(23):3836-41. PMID: 19597027.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    222. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009 Oct; 45(10):e155-60. PMID: 19586795; PMCID: PMC2749898.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    223. Vokes EE, Senan S, Treat JA, Iscoe NA. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer. 2009 May; 10(3):193-8. PMID: 19443340.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    224. Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009 Apr 15; 115(8):1713-22. PMID: 19208430; PMCID: PMC5142442.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    225. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31. PMID: 19318576; PMCID: PMC2871252.
      Citations: 123     Fields:    Translation:HumansAnimalsCells
    226. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10; 27(11):1864-71. PMID: 19289630.
      Citations: 122     Fields:    Translation:HumansCTClinical Trials
    227. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57. PMID: 19201650; PMCID: PMC2768532.
      Citations: 97     Fields:    Translation:HumansCTClinical Trials
    228. Govindan R, Wang X, Baggstrom MQ, Burdette-Radoux S, Hodgson L, Vokes EE, Green MR, Cancer and Leukemia Group B. A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. J Thorac Oncol. 2009 Feb; 4(2):220-6. PMID: 19179900.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    229. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14. PMID: 19139719; PMCID: PMC2741690.
      Citations: 41     Fields:    Translation:HumansCells
    230. Faoro L, Cervantes GM, Ferguson BD, Seiwert TY, Yala S, Vigneswaran WT, Westerhoff M, Tretiakova MS, Ferguson MK, Moura GL, Husain AN, Vokes EE, Salgia R. MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. J Carcinog. 2009; 8:15. PMID: 19955662; PMCID: PMC2791827.
      Citations: 1     
    231. Brizel DM, Vokes EE. Induction chemotherapy: to use or not to use? That is the question. Semin Radiat Oncol. 2009 Jan; 19(1):11-6. PMID: 19028340.
      Citations: 6     Fields:    Translation:Humans
    232. Kindler HL, Aklilu M, Nattam S, Vokes EE. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol. 2008 Dec; 31(6):553-6. PMID: 19060586.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    233. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008 Dec; 47(12):1025-37. PMID: 18709663; PMCID: PMC2583960.
      Citations: 126     Fields:    Translation:HumansCells
    234. Stinchcombe TE, Mauer AM, Hodgson LD, Herndon JE, Lynch TJ, Green MR, Vokes EE, Cancer and Leukemia Group B. Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. J Thorac Oncol. 2008 Nov; 3(11):1301-7. PMID: 18978566; PMCID: PMC2696476.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    235. Wakelee H, Kernstine K, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Goss G, Gaspar L, Gandara DR, Choy H, Putnam JB. Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):346-51. PMID: 19073517.
      Citations: 7     Fields:    Translation:Humans
    236. Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, Edelman MJ, Bolger M, Vokes EE, Green MR, Cancer and Leukemia Group B (CALGB). Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol. 2008 Oct; 3(10):1159-65. PMID: 18827613.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    237. Salama JK, Stenson KM, List MA, Mell LK, Maccracken E, Cohen EE, Blair E, Vokes EE, Haraf DJ. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5. PMID: 18936351.
      Citations: 17     Fields:    Translation:Humans
    238. Faoro L, Loganathan S, Westerhoff M, Modi R, Husain AN, Tretiakova M, Seiwert T, Kindler HL, Vokes EE, Salgia R. Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8. PMID: 18765998; PMCID: PMC2605682.
      Citations: 5     Fields:    Translation:HumansCells
    239. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 01; 26(31):5043-51. PMID: 18809614; PMCID: PMC2652093.
      Citations: 322     Fields:    Translation:Humans
    240. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11. PMID: 18758303; PMCID: PMC4535721.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    241. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9. PMID: 18698045.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    242. Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol. 2008 Aug; 3(8):917-28. PMID: 18670313.
      Citations: 31     Fields:    Translation:Humans
    243. Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 2009 Feb; 63(2):169-79. PMID: 18672314; PMCID: PMC2659375.
      Citations: 47     Fields:    Translation:Humans
    244. Cohn AB, Lang PO, Agarwal JP, Peng SL, Alizadeh K, Stenson KM, Haraf DJ, Cohen EEW, Vokes EE, Gottlieb LJ. Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-132. PMID: 18594395.
      Citations: 7     Fields:    Translation:Humans
    245. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13. PMID: 18541897; PMCID: PMC4859206.
      Citations: 228     Fields:    Translation:HumansCTClinical Trials
    246. Salama JK, Vokes EE. Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol. 2008 Jun; 35(3):251-61. PMID: 18544440.
      Citations: 9     Fields:    Translation:Humans
    247. Vokes EE, Cohen EE, Grandis JR. Introduction: head and neck cancer. Semin Oncol. 2008 Jun; 35(3):196-7. PMID: 18544434.
      Citations:    Fields:    Translation:Humans
    248. Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008 May 20; 26(15):2457-63. PMID: 18487565.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    249. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF, Chicago Phase II Consortium, PMH Phase II Consortium, California Phase II Consortium. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55. PMID: 18423560; PMCID: PMC2699608.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    250. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41. PMID: 18375903.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    251. Kratzke RA, Wang X, Wong L, Kratzke MG, Green MR, Vokes EE, Vogelzang NJ, Kindler HL, Kern JA, Cancer and Leukemia Group B. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008 Apr; 3(4):417-21. PMID: 18379362.
      Citations: 6     Fields:    Translation:HumansCells
    252. Bogart JA, Watson D, McClay EF, Evans L, Herndon JE, Laurie F, Seagren SL, Fitzgerald TJ, Vokes E, Green MR. Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer. 2008 Oct; 62(1):92-8. PMID: 18367288; PMCID: PMC4465446.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    253. Vokes EE. Combining radiotherapy with systemic therapies. Clin Adv Hematol Oncol. 2008 Mar; 6(3):167-9. PMID: 18391914.
      Citations:    Fields:    Translation:Humans
    254. Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer. 2008 Mar; 9(2):85-91. PMID: 18501094.
      Citations: 2     Fields:    Translation:Humans
    255. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27. PMID: 18309947; PMCID: PMC5846189.
      Citations: 87     Fields:    Translation:Humans
    256. Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008 Feb 20; 26(6):870-6. PMID: 18281659; PMCID: PMC3715075.
      Citations: 59     Fields:    Translation:HumansCTClinical Trials
    257. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008 Feb 20; 26(6):848-55. PMID: 18281656.
      Citations: 93     Fields:    Translation:HumansCellsCTClinical Trials
    258. Graziano SL, Herndon JE, Socinski MA, Wang X, Watson D, Vokes E, Green MR, Cancer and Leukemia Group B. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol. 2008 Feb; 3(2):158-62. PMID: 18303437.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    259. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, Soulii L, Bindokas VP, Szeto LL, Gordon GJ, Bueno R, Sugarbaker D, Lingen MW, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes EE, Ferguson MK, Husain AN, Salgia R. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42. PMID: 18172305; PMCID: PMC2767335.
      Citations: 65     Fields:    Translation:HumansAnimals
    260. Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67. PMID: 18166842; PMCID: PMC3742080.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    261. Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd F, Choy H, Gandara DR. Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):9-15. PMID: 18282352.
      Citations: 1     Fields:    Translation:Humans
    262. Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 2008 Jan-Feb; 58(1):32-53. PMID: 18096865.
      Citations: 39     Fields:    Translation:Humans
    263. Langerman A, Maccracken E, Kasza K, Haraf DJ, Vokes EE, Stenson KM. Aspiration in chemoradiated patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007 Dec; 133(12):1289-95. PMID: 18086974.
      Citations: 30     Fields:    Translation:Humans
    264. Yount S, List M, Du H, Yost K, Bode R, Brockstein B, Argiris A, Vokes E, Cohen EE, Campbell B, Valenzuela V, George J, Egan R, Chen J, Meddis D, Cella D. A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26. PMID: 17922221.
      Citations: 9     Fields:    Translation:Humans
    265. Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8. PMID: 17909356.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    266. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007 Sep 10; 25(26):4118-26. PMID: 17827462.
      Citations: 26     Fields:    Translation:HumansAnimals
    267. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007 Sep 01; 25(25):3978-84. PMID: 17761983.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    268. Seiwert TY, Cohen EE, Haraf DJ, Stenson K, Blair EA, Mauer A, Dekker A, Vokes EE. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44. PMID: 17882655.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    269. Lazarus C, Logemann JA, Pauloski BR, Rademaker AW, Helenowski IB, Vonesh EF, Maccracken E, Mittal BB, Vokes EE, Haraf DJ. Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer. Head Neck. 2007 Jul; 29(7):632-7. PMID: 17230558.
      Citations: 34     Fields:    Translation:Humans
    270. Miller AA, Wang XF, Bogart JA, Hodgson LD, Rocha Lima CM, Radford JE, Vokes EE, Green MR, Cancer and Leukemia Group B (CALGB). Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol. 2007 Jul; 2(7):645-51. PMID: 17607121.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    271. Vokes EE, Herndon JE, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR, Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 01; 25(13):1698-704. PMID: 17404369.
      Citations: 122     Fields:    Translation:Humans
    272. Posadas EM, Undevia S, Manchen E, Wade JL, Colevas AD, Karrison T, Vokes EE, Stadler WM. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3. PMID: 17457044.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    273. Cohen EE, Rosine D, Haraf DJ, Loh E, Shen L, Lusinchi A, Vokes EE, Bourhis J. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84. PMID: 17293229.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    274. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007 Mar; 4(3):156-71. PMID: 17327856.
      Citations: 81     Fields:    Translation:Humans
    275. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol. 2007 Feb; 4(2):86-100. PMID: 17259930.
      Citations: 137     Fields:    Translation:Humans
    276. Choong NW, Salgia R, Vokes EE. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S52-60. PMID: 17382025.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    277. Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22. PMID: 17255273.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    278. Harari PM, Cohen RB, Raben D, Myers JN, Vokes EE, Weber RS, Ang KK. The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. Int J Radiat Oncol Biol Phys. 2007; 69(2 Suppl):S1-3. PMID: 17848271.
      Citations:    Fields:    Translation:HumansPHPublic Health
    279. Perry MC, Kohman LJ, Bonner JA, Gu L, Wang X, Vokes EE, Green MR. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. Clin Lung Cancer. 2007 Jan; 8(4):268-72. PMID: 17311692.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    280. Vokes E, Herbst R, Sandler A. Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol. 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PMID: 17143257.
      Citations: 1     Fields:    Translation:Humans
    281. Cohen EE, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44. PMID: 16849759; PMCID: PMC4430103.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    282. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes E. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70. PMID: 16760642.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    283. Vokes EE, Perry MC, Kindler HL, Green MR. The cancer and leukemia group B respiratory committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3581s-8s. PMID: 16740789.
      Citations: 1     Fields:    Translation:Humans
    284. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9. PMID: 16596227.
      Citations: 27     Fields:    Translation:HumansCells
    285. Milano MT, Vokes EE, Kao J, Jackson W, List MA, Stenson KM, Witt ME, Dekker A, MacCracken E, Garofalo MC, Chmura SJ, Weichselbaum RR, Haraf DJ. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51. PMID: 16596230.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    286. Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4. PMID: 16636339.
      Citations: 14     Fields:    Translation:Humans
    287. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50. PMID: 16595780.
      Citations: 92     Fields:    Translation:HumansCTClinical Trials
    288. Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park). 2006 Apr; 20(5 Suppl 2):15-25. PMID: 16736979.
      Citations: 40     Fields:    Translation:Humans
    289. Ryan CW, Dolan ME, Brockstein BB, McLendon R, Delaney SM, Samuels BL, Agamah ES, Vokes EE. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 2006 Nov; 58(5):634-9. PMID: 16520986.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    290. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. PMID: 16533781.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    291. Peterson AC, Harlin H, Karrison T, Vogelzang NJ, Knost JA, Kugler JW, Lester E, Vokes E, Gajewski TF, Stadler WM, University of Chicago Phase II Consortium. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9. PMID: 16514482.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    292. Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD, Villano JL, Kozloff M, Wade JL, Sciortino DF, Szeto L, Vokes EE. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):245-51. PMID: 17409864.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    293. Stenson KM, Huo D, Blair E, Cohen EE, Argiris A, Haraf DJ, Vokes EE. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6. PMID: 16481805.
      Citations: 9     Fields:    Translation:Humans
    294. Logemann JA, Rademaker AW, Pauloski BR, Lazarus CL, Mittal BB, Brockstein B, MacCracken E, Haraf DJ, Vokes EE, Newman LA, Liu D. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck. 2006 Jan; 28(1):64-73. PMID: 16302193; PMCID: PMC1380204.
      Citations: 55     Fields:    Translation:Humans
    295. Blackstock AW, Herndon JE, Paskett ED, Miller AA, Lathan C, Niell HB, Socinski MA, Vokes EE, Green MR, Cancer and Leukemia Group B. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol. 2006 Jan 20; 24(3):407-12. PMID: 16365181.
      Citations: 13     Fields:    Translation:Humans
    296. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ, American Society of Clinical Oncology, Hao D. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006 Jan 01; 24(1):190-205. PMID: 16326753.
      Citations: 30     Fields:    Translation:Humans
    297. Choong NW, Vokes EE. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S98-104. PMID: 16384544.
      Citations: 2     Fields:    Translation:Humans
    298. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24. PMID: 16322304.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    299. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8. PMID: 16299242.
      Citations: 48     Fields:    Translation:HumansCells
    300. Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, Vokes EE. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res. 2005 Nov 01; 11(21):7861-5. PMID: 16278409.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    301. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40. PMID: 16258101.
      Citations: 149     Fields:    Translation:HumansCTClinical Trials
    302. Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, Kaklamani V, Baddi L, Siddiqui FS, Frankel W, Prior TW, Schuller DE, Agrawal A, Lang J, Dolan ME, Vokes EE, Lane WS, Huang CC, Caldes T, Di Cristofano A, Hampel H, Nilsson I, von Heijne G, Fodde R, Murty VV, de la Chapelle A, Weghorst CM. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA. 2005 Oct 05; 294(13):1634-46. PMID: 16204663.
      Citations: 48     Fields:    Translation:HumansCells
    303. Salama JK, Vokes EE, Chmura SJ, Milano MT, Kao J, Stenson KM, Witt ME, Haraf DJ. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):382-91. PMID: 16213104.
      Citations: 63     Fields:    Translation:Humans
    304. Kindler HL, Tothy PK, Wolff R, McCormack RA, Abbruzzese JL, Mani S, Wade-Oliver KT, Vokes EE. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs. 2005 Oct; 23(5):489-93. PMID: 16133801.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    305. Vokes E. Seeking improved outcome in the curative treatment of non-small-cell lung cancer. Lung Cancer. 2005 Oct; 50 Suppl 1:S20-2. PMID: 16291428.
      Citations:    Fields:    Translation:Humans
    306. Vokes EE. Optimal therapy for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2005 Sep 01; 23(25):5853-5. PMID: 16087940.
      Citations: 5     Fields:    Translation:Humans
    307. Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes EE. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol. 2005 Aug; 28(4):340-4. PMID: 16062074.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    308. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Aug 20; 23(24):5578-87. PMID: 16009949.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    309. Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s. PMID: 16000599.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    310. Vokes EE, Crawford J, Bogart J, Socinski MA, Clamon G, Green MR. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5045s-5050s. PMID: 16000612.
      Citations: 3     Fields:    Translation:Humans
    311. Akerley W, Herndon JE, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer. 2005 Jul; 7(1):47-53. PMID: 16098244.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    312. Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR, Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005 Jun 01; 23(16):3752-9. PMID: 15923572.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    313. Desai AA, Kindler HL, Taber D, Agamah E, Mani S, Wade-Oliver K, Ratain MJ, Vokes EE. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6. PMID: 15895230.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    314. Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, Stadler WM. A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol. 2005 May-Jun; 23(3):150-4. PMID: 15907713.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    315. Milano MT, Vokes EE, Salama JK, Stenson KM, Kao J, Witt ME, Mittal BB, Argiris A, Weichselbaum RR, Haraf DJ. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106. PMID: 15752889.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    316. Salama JK, Haraf DJ, Stenson K, Milano MT, Witt ME, Vokes EE. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005 Mar-Apr; 11(2):140-6. PMID: 15969989.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    317. Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL, Hotte SJ. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005 Jan 20; 23(3):585-90. PMID: 15659505.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    318. Vokes E. Current treatments and promising investigations in a multidisciplinary setting. Ann Oncol. 2005; 16 Suppl 6:vi25-vi30. PMID: 15987993.
      Citations: 2     Fields:    Translation:Humans
    319. Brockstein B, Vokes EE. Concurrent chemoradiotherapy for head and neck cancer. Semin Oncol. 2004 Dec; 31(6):786-93. PMID: 15599856.
      Citations: 3     Fields:    Translation:Humans
    320. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83. PMID: 15547705.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    321. Vokes EE, Lingen MW. Update in head and neck oncology. Semin Oncol. 2004 Dec; 31(6):717. PMID: 15599848.
      Citations:    Fields:    Translation:Humans
    322. Kindler HL, Avadhani A, Wade-Oliver K, Karrison T, Mani S, Vokes EE. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug; 22(3):323-7. PMID: 15122080.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    323. Milano MT, Haraf DJ, Stenson KM, Witt ME, Eng C, Mittal BB, Argiris A, Pelzer H, Kozloff MF, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32. PMID: 15297392.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    324. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15; 22(14):2918-26. PMID: 15254061.
      Citations: 168     Fields:    Translation:Humans
    325. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8. PMID: 15221817.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    326. Ryan CW, Vogelzang NJ, Vokes EE, Kindler HL, Undevia SD, Humerickhouse R, Wang Q, Carr RA, Ratain MJ, André AK. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11. PMID: 15240529.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    327. Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EE. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70. PMID: 15161690.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    328. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52. PMID: 15117998.
      Citations: 68     Fields:    Translation:Humans
    329. Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, Jayaram P, Portugal L, Wenig BL, Rosen FR, Haraf DJ, Vokes EE. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55. PMID: 15122662.
      Citations: 28     Fields:    Translation:Humans
    330. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62. PMID: 15041712.
      Citations: 58     Fields:    Translation:Humans
    331. Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol. 2004 Mar 15; 22(6):1110-7. PMID: 15020613.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    332. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Rudin CM, Vokes EE, Ratain MJ, Ramírez J. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8. PMID: 15007088.
      Citations: 269     Fields:    Translation:Humans
    333. List MA, Rutherford JL, Stracks J, Pauloski BR, Logemann JA, Lundy D, Sullivan P, Goodwin W, Kies M, Vokes EE. Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients. Head Neck. 2004 Feb; 26(2):163-70. PMID: 14762885.
      Citations: 21     Fields:    Translation:Humans
    334. Kim ES, Vokes EE, Kies MS. Cetuximab in cancers of the lung and head & neck. Semin Oncol. 2004 Feb; 31(1 Suppl 1):61-7. PMID: 14981582.
      Citations: 3     Fields:    Translation:Humans
    335. Cohen EE, Vokes EE. Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):81-90. PMID: 15005282.
      Citations: 2     Fields:    Translation:Humans
    336. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004 Jan 01; 22(1):77-85. PMID: 14701768.
      Citations: 235     Fields:    Translation:HumansCTClinical Trials
    337. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71. PMID: 14692025.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    338. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004 Jan 01; 22(1):115-9. PMID: 14701773.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    339. Haraf DJ, Rosen FR, Stenson K, Argiris A, Mittal BB, Witt ME, Brockstein BE, List MA, Portugal L, Pelzer H, Weichselbaum RR, Vokes EE. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43. PMID: 14676118.
      Citations: 13     Fields:    Translation:Humans
    340. Mittal BB, Pauloski BR, Haraf DJ, Pelzer HJ, Argiris A, Vokes EE, Rademaker A, Logemann JA. Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1219-30. PMID: 14630255.
      Citations: 48     Fields:    Translation:HumansPHPublic Health
    341. Ready NE, Vokes EE. Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. Lung Cancer. 2003 Dec; 42 Suppl 1:S65-9. PMID: 14611917.
      Citations: 1     Fields:    Translation:Humans
    342. Vokes EE, Stenson KM. Therapeutic options for laryngeal cancer. N Engl J Med. 2003 Nov 27; 349(22):2087-9. PMID: 14645634.
      Citations: 6     Fields:    Translation:Humans
    343. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003 Dec 15; 21(24):4546-52. PMID: 14597742; PMCID: PMC4523388.
      Citations: 36     Fields:    Translation:HumansCellsCTClinical Trials
    344. Lamont EB, Hayreh D, Pickett KE, Dignam JJ, List MA, Stenson KM, Haraf DJ, Brockstein BE, Sellergren SA, Vokes EE. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5. PMID: 13130112.
      Citations: 56     Fields:    Translation:Humans
    345. Vokes EE, Choy H. Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. Lung Cancer. 2003 Aug; 41 Suppl 1:S115-21. PMID: 12867070.
      Citations: 3     Fields:    Translation:Humans
    346. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7. PMID: 12743152.
      Citations: 143     Fields:    Translation:HumansCTClinical Trials
    347. Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erlichman C, Kaufmann SH, Vokes EE. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003 May 01; 21(9):1760-6. PMID: 12721252.
      Citations: 58     Fields:    Translation:HumansCellsCTClinical Trials
    348. Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, Brockstein BE, Mittal BB, Rademaker AW, Witt ME, Pelzer H, Weichselbaum RR, Vokes EE. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97. PMID: 12738722.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    349. Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, Vokes EE. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):191-6. PMID: 12581572.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    350. Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6. PMID: 12525525.
      Citations: 41     Fields:    Translation:Humans
    351. Argiris A, Haraf DJ, Kies MS, Vokes EE. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist. 2003; 8(4):350-60. PMID: 12897332.
      Citations: 13     Fields:    Translation:Humans
    352. Vokes EE, Choy H, Gandara D, Mattson K. Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer. 2002 Dec; 38 Suppl 4:29-35. PMID: 12480192.
      Citations: 3     Fields:    Translation:Humans
    353. Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR, Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002 Oct 15; 20(20):4191-8. PMID: 12377962.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    354. Hoffman PC, Cohen EE, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D, Vokes EE, Hoffman PC, Cohen EE, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D, Vokes EE. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71. PMID: 12367795.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    355. Villano JL, List MA, Vokes EE. The importance of quality-of-life measurements in oncology. Clin Lung Cancer. 2002 Sep; 4(2):110. PMID: 14653867.
      Citations:    Fields:    
    356. Rosen F, Vokes EE, Rosen F, Vokes EE. Curative treatment for advanced head and neck cancer in the community: has the time come? Cancer J. 2002 Jul-Aug; 8(4):298-300. PMID: 12184406.
      Citations:    Fields:    Translation:Humans
    357. List MA, Lee Rutherford J, Stracks J, Haraf D, Kies MS, Vokes EE. An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck. Cancer. 2002 Jul 01; 95(1):98-104. PMID: 12115322.
      Citations: 18     Fields:    Translation:Humans
    358. Ryan CW, Vokes EE, Vogelzang NJ, Janisch L, Kobayashi K, Ratain MJ. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5. PMID: 12111104.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    359. Vokes EE, Charoentum C, Gordon GS, Rudin CM, Krauss SA, Hoffman PC, Mauer AM, Lee S, Watson S. Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3(4):265-70. PMID: 14662035.
      Citations:    Fields:    
    360. Cohen EE, Vokes EE. Searching for a standard. J Clin Oncol. 2002 Jan 15; 20(2):359-61. PMID: 11786560.
      Citations:    Fields:    Translation:Humans
    361. E Vokes E, E Vokes E. Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer. Lung Cancer. 2001 Sep; 33 Suppl 1:S85-9. PMID: 11576712.
      Citations:    Fields:    Translation:Humans
    362. Hainsworth JD, Vokes EE. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Semin Oncol. 2001 Feb; 28 Suppl 2:22-27. PMID: 28140078.
      Citations:    Fields:    
    363. Vokes EE, Gordon GS, Rudin CM, Mauer AM, Watson S, Krauss S, Arrieta R, Golomb HM, Hoffman PC. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs. 2001; 19(4):329-33. PMID: 11561694.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    364. Vokes EE. Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. Oncologist. 2001; 6 Suppl 1:25-7. PMID: 11182002.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    365. Vokes EE, Gordon GS, Mauer AM, Rudin CM, Krauss SA, Szeto L, Golomb HM, Hoffman PC. A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. Clin Lung Cancer. 2000 Nov; 2(2):128-32. PMID: 14731323.
      Citations: 3     Fields:    
    366. Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, Humerickhouse R, Dolan ME, Pelzer H, Sulzen L, Witt ME, Hsieh YC, Mittal BB, Weichselbaum RR. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61. PMID: 10764425.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    Vokes's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (698)
    Explore
    _
    Co-Authors (104)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _